Pharmacological approaches for management of neuropathic pain in children
DOI:
https://doi.org/10.14748/q8957163Keywords:
neuropathic pain, pediatrics, pharmacological therapy, personalized treatmentAbstract
Introduction: Neuropathic pain in children is a significant challenge to medical practice due to difficulties in diagnosis and limitations of pharmacological therapies.
Aim: The review aimed to summarize the current knowledge about the pharmacological treatment of neuropathic pain in children and adolescents.
Materials and Methods: Scientific publications from the last 15 years, including clinical cases, results of clinical trials and systematic reviews, were included in the current article. Resources such as PubMed and UpToDate were used for the search. It was performed by using the keywords “neuropathic pain in children”, “pediatric therapy”, “topical treatments”, “pharmacological therapy”, and “personalized treatment”.
Results: The review briefly describes the main causes of neuropathic pain in children, the specific clinical signs of that kind of pain, and the diagnostic approaches in the pediatric population. Attention is paid to scales used in clinical practice for assessing pain intensity. The emphasis is set on pharmacological treatment with a focus on current data on the efficacy of main drug groups used for alleviation of neuropathic pain in children: gabapentinoids, which remain the most commonly used drugs; some antidepressants, particularly suitable for children with accompanying mood disorders; opioid analgesics, especially those with additional mechanisms of action; and lidocaine applied topically or in the form of intravenous infusions. In addition, the prospect of personalized treatment based on pain phenotyping through quantitative sensory testing is discussed.
Conclusion: Management of neuropathic pain in children includes pharmacological and non-pharmacological methods. It requires an interdisciplinary and individualized approach and development of evidence-based therapeutic strategies.
References
[1] International Association for the Study of Pain. IASP Terminology. Available at: https://www.iasp-pain.org/terminology?navItemNumber=576#Pain
[2] Einhorn LM, Hudon J, Ingelmo P. The Pharmacological Treatment of Neuropathic Pain in Children. Curr Neuropharmacol. 2024; 22(1):38-52. doi: 10.2174/1570159X21666230804110858.
[3] Finnerup NB, Kuner R, Jensen TS. Neuropathic Pain: From Mechanisms to Treatment. Physiol Rev. 2021 Jan 1;101(1):259-301. doi: 10.1152/physrev.00045.2019.
[4] Hockenberry M, Wilson D, Rodgers CC. Wong's Essentials of Pediatric Nursing. 10th Ed. St. Louis: Mosby; 2016
[5] Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997 May-Jun;23(3):293-7.
[6] Kliegman RM, St Geme III JW . Nelson Textbook of Pediatrics, 22nd Ed . Elsevier. 2024
[7] Donado C, Nedeljkovic K, Wangnamthip S, Solodiuk JC, Bourgeois FT, Berde CB. Trends in Gabapentin and Pregabalin Prescribing in a Tertiary Pediatric Medical Center. Hosp Pediatr. 2021 Aug;11(8):909-914. doi: 10.1542/hpeds.2020-003582.
[8] Akkurt HE, Gümüş H, Göksu H, Odabaşı ÖF, Yılmaz H. Gabapentin Treatment for Neuropathic Pain in a Child with Sciatic Nerve Injury. Case Rep Med. 2015;2015:873157. doi: 10.1155/2015/873157.
[9] Kaul I, Amin A, Rosenberg M, Rosenberg L, Meyer WJ 3rd. Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review. Burns. 2018 Mar;44(2):414-422. doi: 10.1016/j.burns.2017.07.018.
[10] Anghelescu DL, Tesney JM, Jeha S, Wright BB, Trujillo L, Sandlund JT, et al . Prospective randomized trial of interventions for vincristine-related neuropathic pain. Pediatr Blood Cancer. 2020 Sep;67(9):e28539. doi: 10.1002/pbc.28539.
[11] Anghelescu DL, Tesney JM. Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. Paediatr Drugs. 2019 Apr;21(2):59-70. doi: 10.1007/s40272-018-00324-4.
[12] Friedrichsdorf SJ, Nugent AP. Management of neuropathic pain in children with cancer. Curr Opin Support Palliative Care. 2013 Jun;7(2):131-8. doi: 10.1097/SPC.0b013e3283615ebe.
[13] Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behavior, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019 Jun 12;365:l2147. doi: 10.1136/bmj.l2147.
[14] Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, et al . Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neurosci Ther. 2016 Jul;22(7):568-76. doi: 10.1111/cns.12542.
[15] Brown S, Johnston B, Amaria K, Watkins J, Campbell F, Pehora C, et al . A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. Scand J Pain. 2016 Oct;13:156-63. doi: 10.1016/j.sjpain.2016.05.039.
[16] Upadhyaya HP, Arnold LM, Alaka K, Qiao M, Williams D, Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial. Pediatr Rheumatol Online J. 2019 May 28;17(1):27. doi: 10.1186/s12969-019-0325-6.
[17] Burghardt KJ, Thomas ST, Tutag-Lehr V. Off-label use of duloxetine for pediatric neuropathic pain. Ment. Health Clin. 2015;5(6):277–283. doi: 10.9740/mhc.2015.11.277.
[18] Kachko L, Ben Ami S, Liberman A, Birk E, Kronenberg S. Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid 'reactive depression' in an adolescent. Pain Res Manag. 2011 Nov-Dec;16(6):457-9. doi: 10.1155/2011/164984.
[19] FDA Drug Safety Communication. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020281s039lbl.pd
[20] Finkel JC, Goldberg J, Rosenburg R, Ariyawansa J, Sun T, Ochs-Ross R, et al. . First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. J. Pain Res. 2019;12:1925–1936. doi: 10.2147/JPR.S197348.
[21] Muse D, Tarau E, Lefeber C, Sohns M, Brett M, Goldberg J, et al. . Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients. J Pain Res. 2019 May 31;12:1777-1790. doi: 10.2147/JPR.S197039.
[22] Windsor RB, Tham SW, Adams TL, Anderson A. The Use of Opioids for Treatment of Pediatric Neuropathic Pain: A Literature Review. Clin J Pain. 2019 Jun;35(6):509-514. doi: 10.1097/AJP.0000000000000712.
[23] Vo T, Rice ASC, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain. 2009 Jun;143(3):169-71. doi: 10.1016/j.pain.2009.03.013.
[24] Yang X, Wei X, Mu Y, Li Q, Liu J. A review of the mechanism of the central analgesic effect of lidocaine. Medicine (Baltimore). 2020 Apr;99(17):e19898. doi: 10.1097/MD.0000000000019898..
[25] Rasolofo J, Poncelet M, Rousseau V, Marec-Berard P. Efficacy des emplâtres de lidocaïne 5 % sur les douleurs des crises vaso-occlusives chez l'enfant drépanocytaire [Analgesic efficacy of topical lidocaine for vaso-occlusive crisis in children with sickle cell disease]. Arch Pediatr. 2013 Jul;20(7):762-7. French. doi: 10.1016/j.arcped.2013.04.013.
[26] Rousseau V, Morelle M, Arriuberge C, Darnis S, Chabaud S, Launay V, et al . Efficacy and Tolerance of Lidocaine 5% Patches in Neuropathic Pain and Pain Related to Vaso-occlusive Sickle Cell Crises in Children: A Prospective Multicenter Clinical Study. Pain Pract. 2018 Jul;18(6):788-797. doi: 10.1111/papr.12674.
[27] Goddard JM, Reaney RL. Lidocaine 5%-medicated plaster (Versatis) for localized neuropathic pain: results of a multicentre evaluation of use in children and adolescents. Br J Pain. 2018 Aug;12(3):189-193. doi: 10.1177/2049463718756431.
[28] Hutson P, Backonja M, Knurr H. Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy. Pain Med. 2015 Mar;16(3):531-6. doi: 10.1111/pme.12642.
[29] Kim YC, Castañeda AM, Lee CS, Jin HS, Park KS, Moon JY. Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study. Reg Anesth Pain Med. 2018 May;43(4):415-424. doi: 10.1097/AAP.0000000000000741.
[30] Mooney JJ, Pagel PS, Kundu A. Safety, tolerability, and short-term efficacy of intravenous lidocaine infusions for the treatment of chronic pain in adolescents and young adults: a preliminary report. Pain Med. 2014 May;15(5):820-5. doi: 10.1111/pme.12333.
[31] Puri L, Morgan KJ, Anghelescu DL. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease. Curr Opin Support Palliative Care. 2019 Dec;13(4):402-407. doi: 10.1097/SPC.0000000000000437.
[32] Kajiume T, Sera Y, Nakanuno R, Ogura T, Karakawa S, Kobayakawa M, et al . Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. J Palliat Med. 2012 Jun;15(6):719-22. doi: 10.1089/jpm.2011.0097.
[33] Gibbons K, DeMonbrun A, Beckman EJ, Keefer P, Wagner D, Stewart M, et al. Continuous Lidocaine Infusions to Manage Opioid-Refractory Pain in a Series of Cancer Patients in a Pediatric Hospital. Pediatr Blood Cancer. 2016 Jul;63(7):1168-74. doi: 10.1002/pbc.25870.
[34] Featherly J, Baxter Wojnowicz S, Steidl K, Burgess J. Lidocaine for dinutuximab-associated pain? A multicenter retrospective observational cohort study. Pediatr Blood Cancer. 2022 Sep;69(9):e29653. doi: 10.1002/pbc.29653.
[35] Baber N, Pritchard D.. Dose estimation for children. British Journal of Clinical Pharmacology 2003 ; 56(5), 489–493. doi : 10.1046/j.1365-2125.2003.01901.x
[36] Dhaliwal JS, Spurling BC, Molla M. Duloxetine. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549806/
[37] Hall EA, Sauer HE, Davis MS, Anghelescu DL. Lidocaine Infusions for Pain Management in Pediatrics. Paediatr Drugs. 2021 Jul;23(4):349-359. doi: 10.1007/s40272-021-00454-2.
[38] Bruneau A, Ferland CE, Pérez-Medina-Carballo R, Somaini M, Mohamed N, Curatolo M, et al . Association between the Use of Quantitative Sensory Testing and Conditioned Pain Modulation and the Prescription of Medication and Interventional Procedures in Children with Chronic Pain Conditions. Children (Basel). 2022 Aug 2;9(8):1157. doi: 10.3390/children9081157.
